Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer&#39;s disease, positive for plasma p-tau217.

Undisclosed tau antibody therapeutic - Axon Neurosci

AADvac1 - Axon Neurosci

http://www.ncbi.nlm.nih.gov/pubmed/39580468

Bengt Winblad; Branislav Kovacech; Erik Stoops; Eugeen Vanmechelen; Eva Kontsekova; Howard H Feldman; Jeroen Vanbrabant; Jozef Hanes; Michal Fresser; Nicholas C Cullen; Norbert Zilka; Petr Novák; Stanislav Katina; Vojtech Parrak

Nov 24, 2024